Lupin ropes in Jeffrey Kindler, Alfonso Zulueta as Independent Directors

Zulueta spent over three decades in various roles of increasing responsibility with Eli Lilly and Company, including as Vice President of Global Marketing, President of Global Oncology and Critical Care Products and most recently, as President of International responsible for all geographies outside the United States and Canada. He also served as a corporate officer and member of Eli Lilly and Company’s Executive Committee. Zulueta previously served as member of the board of the European Federation of Pharmaceutical Industries and Associations and the U.S.-Japan Business Council. 

Zulueta currently serves as Non-Executive Chairman of the board of directors of Interpharma Investments Limited, the holding company of Zuellig Pharma, one of the largest healthcare services groups in Asia. He is also president/CEO of CZ Ventures, a company focused on start-up investments, and member of the board of directors at Glooko, CTS Corporation, and Bridge PayDay Solutions.

Zulueta holds an Economics undergraduate degree from De La Salle University, Manila, where he was conferred the 2023 Outstanding Alumnus Award, and MBA degree in Marketing/Finance from the University of Virginia, Darden School of Business, USA.

Commenting on the appointments, Vinita Gupta, Chief Executive Officer, Lupin said, "We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry and deep understanding of the evolving global pharmaceutical landscape, will enable us to advance our growth plans in the years to come."

Read also: Lupin bags USFDA nod for Travoprost Ophthalmic Solution